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ARTICLE SUMMARY

Article focus
Impact of EndoBarrier Gastrointestinal Liner/duodenal-jejunal bypass sleeve (DJBS) on weight loss (percent excess weight loss or weight loss in kilogram), glycaemic control (HbA1c and fasting plasma glucose), safety, lipids and proportion of subjects discontinuing anti-diabetic medication in patients treated with the device.
Key messages
There does not exist a systematic review with meta-analysis on the weight and glucoselowering effect or safety of the DJBS. The current bariatric surgical procedures are effective but associated with short and long-term complications. The need for less invasive and safer but yet effective bariatric treatment modalities are wanted.
Strength and limitations of this study
Despite our groups experience in conducting a systematic review with meta-analysis, small studies with high heterogeneity and varying quality may be this study's limitation.
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For peer review only -http://bmjopen.bmj.com/site/about/guidelines.xhtml 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 In contrast, bariatric surgery has proven effective -also on the longer term -and leads to an improved glucose homeostasis. Patients with type 2 diabetes undergoing bariatric surgery experience improved glycaemic control or remission of diabetes reducing or even eliminating their need for medication 3 .
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Current clinical practice -the bariatic surgical procedure Roux-en-Y gastric bypass Interestingly, rerouting of nutrient flow through the gastrointestinal tract (bypassing the proximal small intestine) following the surgical bariatric procedure Roux-en-Y gastric bypass (RYGB) has been shown to dramatically improve glucose metabolism within few days -prior to any weight loss has occurred -among obese type 2 diabetic patients. Depending on the definition of remission, remission rates of 40 4 to 80% 2 have been reported. The predominant hypotheses on the physiological background for the metabolic advantages after bariatric surgery include changed release of gastrointestinal hormones (increased secretion of hormones with anti-diabetic and/or anti-obesity properties, e.g. glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), and reduced secretion of 'diabetogenic' hormones e.g. glucosedependent insulinotropic peptide (GIP)) combined with surgery-induced restriction of food intake. Despite the short and long-term benefits RYGB provides for obese patients with type 2 diabetes, the procedure -like most other bariatric surgical procedures -is invasive, irreversible and potentially lethal. In a meta-analysis from 2004 Buchwald et al. report a 30-day mortality after gastric banding, RYGB and biliopancreatic diversion of 0.1%, 0.5% and 1.1% respectively 2 . The most frequent short-term causes of mortality after RYGB are venous thromboembolism and cardiorespiratory disease 5 . Additionally several short and long-term complications are associated with the procedures including anastomotic leaks, bleeding, infections, small bowel obstruction, hernias, dumping syndrome and malabsorption of micro and macronutrients 5, 6 . Finding a less invasive bariatric procedure to treat obesity and type 2 diabetes would be of great interest not only for the patients but also for the society in general. The minimal invasive and fully reversible DJBS may represent an alternative to the most commonly used bariatric techniques. With this protocol we intend to investigate the efficacy and safety of DJBS.
Description of the intervention
The EndoBarrier Gastrointestinal Liner (a polymer DJBS) consists of a nickel-titanium anchor and a 60 cm impermeable sleeve made of fluoropolymer (Fig. 1) . The device, which is open at both ends, is endoscopically placed in the duodenum via an over-the-wire system. The anchor is fixed to the intestinal wall within the duodenal bulb by small barbs grasping the intestinal mucosa 7 . Ingested nutrients pass down to the stomach and onwards directly and mostly undigested into the sleeve. Pancreatic and bile juice passes naturally into the intestinal tract, flowing down between the sleeve and the intestinal wall. It mixes together with . Placing the DJBS endoscopically makes the procedure minimal invasive. Furthermore, the DJBS has the advantage of being fully reversible; the device can easily be removed using an endoscope 9 . The producer of the device (GI Dynamics Inc.) recommends that treatment with DJBS is accompanied with dietetic counselling to optimise the effect and to prevent device malfunction. Currently the device is approved for a maximal treatment period of 12 month. In 2010 the DJBS received European CE marking and achieved conditional approval by the US Food and Drug Administration in August 2012.
How the intervention might work
The mechanisms behind the body-weight lowering and the anti-diabetic effects of DJBS are unknown, but are thought to involve less absorption of nutrients and have been speculated to encompass changes in gut hormone secretion. Up to now several human studies with duration from 12 to 52 weeks report that implanted subjects lose weight and achieve improvements in their diabetic state after treatment with the device. Tarnoff et al. reported in their 12 week open-label prospective randomized controlled trial an excess weight loss (EWL) of 22.1% and 5.3% for implanted subjects and subjects treated with a low-calorie diet, respectively 10 . Another randomised sham-controlled trial showed EWL of 11.9% and 2.7% for the device group and the sham group, respectively 8 . Regarding changes in glycaemic parameters both Rodriquez et al. and Schouten et al. have reported improved glycaemic control (greater reduction in glycated haemoglobin A1c (HbA1c)) when treated with DJBS compared to controls 11, 12 . de Jonge et al 13 report in their study of 17 obese subjects with type 2 diabetes that DJBS changes the gut hormone secretion favouring postprandial release of GLP-1 and lowering secretion of GIP within one week after implantation before any significant weight loss occurred. This emphasises that changes in gut hormones may constitute one of the mechanisms by which DJBS exerts anti-diabetic anti-obesity effects.
Why it is important to do this review
As mentioned above, overweight and obesity represent major concerns for the individual and the society. The growing number of obese people has also lead to a worrying increase in the incidence of people with type 2 diabetes. Worldwide nearly 350 million people suffer from this disease 14 . Bariatic surgery has proven to be effective as a method of reducing body weight and improving type 2 diabetes. However, the potentially serious complications during and following the invasive and irreversible surgical procedures are incontrovertible. Thus, there is currently a strong need for new and less invasive, safer and preferably reversible alternatives to bariatric surgical procedures. The DJBS may provide a modality fulfilling these conditions. Current data on the effects of DJBS stem from rather small studies. Therefore it seems of major importance to compile and analyse current evidence of the effect of the DJBS on obesity and/or type 2 diabetes. Such evidence may help guide clinical decision-making and procure better treatment of obesity and type 2 diabetes.
OBJECTIVES
The primary objectives of the present protocol is to evaluate the effect of the DJBS on weight loss as assessed by change from baseline or percent of excess weight lost (%EWL), glycaemic control as assessed by HbA1c, and safety. Secondary objectives include evaluation of the proportion of type 2 diabetic patients being able to reduce or discontinue anti-diabetic 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
METHODS AND ANALYSES
The systematic review will be performed according to the recommendations specified in the Cochrane Handbook for Intervention Reviews 15 . The reporting of the review will follow the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement 16 .
Criteria for considering studies for review
Types of studies The review will include randomised clinical trials, prospective non-randomised trials, casecontrol studies and case series investigating the effects of the DJBS, irrespective of blinding and publication status. Unpublished trials will be included if data and methodology is accessible in written form.
Types of participants
Adult overweight or obese patients (age 18 years or older) with or without type 2 diabetes treated with the DJBS will be included. Preferably the definition of overweight, obesity and type 2 diabetes should follow the criteria from WHO, the European Association for the Study of Diabetes (EASD) or the American Diabetes Association (ADA) 17 , but if necessary, trials will be included using the author's definition of obesity and type 2 diabetes.
Types of interventions
The comparisons will assess implantation of DJBS versus no intervention, sham-endoscopy and/or low-calorie diet.
Types of outcome measures
The outcome measures will be assessed based on analysis of individual patient data from included trials or from published reports when available.
Primary outcomes
• Mean weight loss in kilograms at end of intervention • Change in HbA1c • Safety
Secondary outcomes
• Proportion of type 2 diabetic patients reducing or discontinuing anti-diabetic medication after end of intervention • Change in fasting plasma glucose or fasting blood glucose • Change in total cholesterol 
Search methods for identification of studies
Electronic searches
Electronic searches will be performed in The Cochrane Library, Medline, EMBASE and Web of Science using the strategy below. Only English literature will be included.
• .
Data collection and analysis
Two authors (UR and NH) will independently extract data and resolve disagreements through discussion before analysis. In case of unresolved matters, a third party will be involved. If necessary data are not included in the published trial reports, the authors of the included trial will be contacted for further information.
Selection of studies
The trials identified via electronic and manual searches will be listed. Included trials will be selected using the above mentioned criteria. Trials that are excluded will be listed with the reason for exclusion. All authors participate in the selection of trials.
Data extraction and management
The following data will be extracted from the included trials: 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Assessment of reporting bias
We aim to compare trial protocols with subsequent publications when available and will extract whether clinically relevant outcomes are reported
Assessment of risk of bias in included trials
Due to expected inclusion of different types of studies, the following assessment of risk of bias will be used. For randomised studies randomization methods will be extracted as the primary measure of bias control. The randomization methods will be assessed on the allocation sequence generation (classified as adequate if based on computer-generated random numbers, a table of random numbers or similar), allocation concealment (classified as adequate if randomization was performed through a independent central unit, identically appearing treatments, serially numbered opaque sealed envelopes or similar) and incomplete data outcome (whether all patients were accounted for). With regard to blinding (detection and performance bias) data will be extracted in order to assess whether single or double blinding were performed. Blinding methods will be evaluated (e.g. use of placebo). Persons who were blinded with regard to the intervention will be assessed (i.e. patients, health care providers or other persons involved in the trial). For other types of studies incomplete outcome data (attrition bias), e.g. patients lost to follow up, will be evaluated as a measure of attrition bias. Outcome reporting (reporting bias) -the extent to which clinically relevant outcome measures are reported and differences between trial protocols and subsequent reports -will be evaluated and reported as a marker of reporting bias. Other biases will include sample size calculations and the extent to which the planned sample size was achieved. All non-randomized studies will be classified as high risk of bias.
Measures of treatment effect
Dichotomous data will be analysed using risk differences and continuous data using weighted mean differences, both with 95% confidence intervals. Relative risk will be calculated.
Assessment of heterogeneity
The intertrial heterogeneity will be expressed as I 2 values. The general interpretation of the I 2 values is:
• 0 to 40%: might not be important
• 30 to 60%: may represent moderate heterogeneity
• 50 to 90%: may represent substantial heterogeneity
• 75 to 100%: considerable heterogeneity Intertrial heterogeneity, small study effects and risk of bias will be evaluated via regression analysis (Egger's test).
Dealing with missing data
Intention-to-treat analyses including all patients randomized will be performed. In the case of patients with missing outcome data, the last observation carried forward will be used. Individual patient data will be sought from the original source or from the published trial reports where individual patient data are unavailable. Data analysis STATA (Stata Corp, Texas, USA, version 12) will be used for analyses. The primary metaanalyses will be performed using random effects models due to an expected intertrial heterogeneity.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses will be performed to assess the impact of patient, intervention, trial characteristics and intertrial heterogeneity. The test for subgroup differences will be calculated for all subgroups and the results presented as P and I 2 values, respectively.
Sensitivity analysis
To assess the impact of small trials, fixed effect meta-analyses will be executed. Additional sensitivity analyses with exclusion of trials classified as having unclear adequate randomization will also be performed.
Unit-of-analysis issues
In the analysis each patient will be counted for only once. If necessary the same follow-up time point will be chosen to have as much data as possible to do the analysis even though the follow-up period may be longer for the individual trial. This will increase heterogeneity with regards to follow-up time, but may increase the possibility of reporting bias. Otherwise the longest follow-up will be used.
ETHICS AND DISSEMINATION
This study will evaluate the impact of the DJBS on weight loss, type 2 diabetes (HbA1c) and safety. Furthermore, the effect on fasting plasma or blood glucose, reduction in anti-diabetic medication and changes in blood lipids will be investigated. The study will hopefully shed light on the novel minimally invasive and reversible technique of DJBS and, thus, provide knowledge about the use of it in the treatment of obesity and type 2 diabetes. The study will be disseminated by peer-review publication and conference presentation. 
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